InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,896.02
(
-0.69%
)
Post# of 97239
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

$$$eeker

Send PM Follow Ignore
Followers 29
Posts 2503
Boards Moderated 0
Alias Born 04/09/2010

$$$eeker

Re: None

Tuesday, 12/17/2013 8:09:47 AM

Tuesday, December 17, 2013 8:09:47 AM

Post# of 97239
$ATHX Athersys' MultiStem stem cell therapy receives orphan drug designation in Europe for prevention of graft-versus-host disease
Co announced that the Committee for Orphan Medicinal Products of the European Medicines Agency (:EMA) has issued a positive opinion (EMA/OD/146/13) for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem therapy, for the prevention of graft-versus-host disease (GvHD). The Company is developing its MultiStem cell therapy as a GvHD prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplant and is currently preparing for a Phase II/III clinical study in the area. The MultiStem therapy for the prevention of GvHD has also previously been granted orphan drug designation by the FDA.
http://yhoo.it/19aq4R8
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up